ArticleBritish journal of pharmacology2017
Biphasic effects of propranolol on tumour growth in B16F10 melanoma-bearing mice.
Article in British journal of pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Beta-blocker use and survival outcomes in colorectal cancer patients: A systematic review and meta-analysis.The Journal of international medical research · 2025Pooled it
- Antihypertensive Drugs as Potential Repositioning Options for Melanoma: A Map of Pre-Clinical Evidence.Diseases (Basel, Switzerland) · 2026Review
- Beta-Blocker Use and Survival Outcomes in Pancreatic Cancer Patients: A Systematic Review and Meta-Analysis.Clinical Medicine Insights. Oncology · 2026Article
- Sympathetic axonogenesis promotes adenoid cystic carcinoma progression.The Journal of experimental medicine · 2025Article
- Bioadhesive Eudragit RLPharmaceutics · 2025Article
- Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence.European heart journal · 2024Review
- Crosstalk between β2- and α2-Adrenergic Receptors in the Regulation of B16F10 Melanoma Cell Proliferation.International journal of molecular sciences · 2022Article
- Propranolol suppresses gastric cancer cell growth by regulating proliferation and apoptosis.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2021Article
- Neurobiology of Cancer: Introduction of New Drugs in the Treatment and Prevention of Cancer.International journal of molecular sciences · 2021Review
- β-Adrenoceptor blockade prevents carotid body hyperactivity and elevated vascular sympathetic nerve density induced by chronic intermittent hypoxia.Pflugers Archiv : European journal of physiology · 2021Article
- Article
- β-Adrenoceptor Activation in Breast MCF-10A Cells Induces a Pattern of Catecholamine Production Similar to that of Tumorigenic MCF-7 Cells.International journal of molecular sciences · 2020Article
- Stress-induced Norepinephrine Downregulates CCL2 in Macrophages to Suppress Tumor Growth in a Model of Malignant Melanoma.Cancer prevention research (Philadelphia, Pa.) · 2020Article
- The Role of β-Blockers in Melanoma.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020Review
- β-Adrenoceptors as drug targets in melanoma: novel preclinical evidence for a role of βBritish journal of pharmacology · 2019Review
- The beta adrenergic receptor antagonist propranolol alters mitogenic and apoptotic signaling in late stage breast cancer.Biomedical journal · 2019Article
- Efficient resolution of 3-aryloxy-1,2-propanediols using CLEA-YCJ01 with high enantioselectivity.RSC advances · 2019Article
- Therapeutic Targeting of Cancer Stem Cells via Modulation of the Renin-Angiotensin System.Frontiers in oncology · 2019Review
- Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression.Scientific reports · 2018Article
- Propranolol suppresses the proliferation and induces the apoptosis of liver cancer cells.Molecular medicine reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposePropranolol is a vasoactive drug that shows antiangiogenic and antitumour activities in melanoma. However, it is unknown whether these activities are dose-dependent and whether there is a relationship between systemic vascular effects of propranolol and anti-melanoma activity. EXPERIMENTAL APPROACH: Effects of increasing doses of propranolol (10, 20, 30 and 40 mg·kg KEY
resultsIn vitro analyses revealed that B16F10 cells expressed β-adrenoceptors, but neither isoprenaline, a β-adrenoceptor agonist, nor the β-blocker propranolol affected cancer cell proliferation. In vivo studies showed that the antitumour efficacy of propranolol follows a U-shaped biphasic dose-response curve. Low doses (10 and 20 mg·kg CONCLUSIONS AND IMPLICATIONS: Propranolol inhibits melanoma growth in a U-shaped biphasic manner. A direct relationship exists between SVR and anti-melanoma activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.